stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) Gross margin
Mirum Pharmaceuticals, Inc.'s gross margin over the twelve months to 30 September 2026 was 81.7%, up 1.0 percentage points from fiscal 2025 (80.8%). Over the past ten years it has ranged from 0.00% (fiscal 2020) to 90.1% (fiscal 2021); the current reading is higher than 71% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 80.8% | 5.00 |
| FY2024 | 75.8% | 1.01 |
| FY2023 | 74.8% | (9.18) |
| FY2022 | 83.9% | (6.12) |
| FY2021 | 90.1% | 90.06 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 81.1% | (1.72) |
| Jun 2026 | 82.8% | 0.80 |
| Mar 2026 | 82.0% | 0.96 |
| Dec 2025 | 81.0% | 0.22 |
| 24 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| IONS Ionis Pharmaceuticals, Inc. compare | 98.2% |
| LGND Ligand Pharmaceuticals Incorporated compare | 95.2% |
| PTCT PTC Therapeutics, Inc. compare | 93.2% |
| MIRM Mirum Pharmaceuticals, Inc. | 81.7% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| ORKA Oruka Therapeutics, Inc. compare | 0.00% |
| IMVT Immunovant, Inc. compare | 0.00% |
| CGON CG Oncology, Inc. compare | −85.2% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement